精密科學 EXAS 深 滬
等待開盤 06-25 09:30:00 美东时间
104.91
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 104.91
- 總市值 2003.78万
- 52周最高 104.98
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 38.8118
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 159.54
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.67
- 每 手 1
- 風險率 24.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
Align names Kevin Conroy board chairman as C. Raymond Larkin Jr. retires effective July 1, 2026
Align names Kevin Conroy board chairman as C. Raymond Larkin Jr. retires effective July 1, 2026 Align Technology set a board leadership transition effective July 1, 2026. Chairman C. Raymond Larkin Jr. will retire from the chair role, staying on the board through December 31, 2026. Kevin Conroy will
06-19 09:01
Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination
Nano Dimension Ltd. and Infinite Epigenetics issued a shareholder update detailing their proposed business combination. The update addresses Murchinson Ltd.'s concerns, emphasizing Infinite's proven science, commercial success, and AI-driven platform. The transaction aims to create long-term value by leveraging Infinite's epigenetic data and diagnostics capabilities, while Nano's capital will support its growth and AI development. The combination...
06-16 23:43
Baron Discovery Fund reshuffles portfolio with new additions and exits
Baron Discovery Fund underperformed its benchmark in Q1 2026, falling 10.65% as compared to a 2.81% decline for the Russell 2000 Growth Index. Among portfolio changes, the fund established new positio...
06-09 21:13
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds GSK deal June 9 (Reuters) - GSK GSK.L has agreed to buy cancer drug developer Nuvalent NUVL.O for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-ter
06-09 17:13
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics appoints Raj Jampa as Chief Technology Officer, effective June 1, 2026. Jampa will oversee the company's technology strategy, leveraging AI to enhance efficiency and innovation. With a background in leading large-scale transformations at Agilent Technologies, Exact Sciences, and Genomic Health, Jampa is expected to strengthen Myriad's digital foundation and support growth in molecular diagnostics and precision medicine.
06-02 13:05
美国癌症协会再次认可Cologuard——这是否终于增强了雅培的投资理由？
雅培与Exact Sciences的交易接近完成，Exact Sciences已获监管批准，股东于2月20日批准，合并预计3月23日或二季度末前完成。当前焦点从...
05-31 06:08
Blood test added to US colorectal cancer screening options
Blood test added to US colorectal cancer screening options American Cancer Society updated guideline published on Wednesday Colonoscopy remains the gold standard for colorectal cancer screening Alternatives now include a blood test and at-home stool tests. By Nancy Lapid May 27 (Reuters) - People wh
05-27 19:00
雅培(ABT)股票5月18日盘中上涨3.04%：真相来了
• 雅培2026财年第一季度的利润和营收均超预期。 • 对Exact Sciences的收购巩固了其在癌症诊断市场的地位。 • 该公司重申了2026财年的业绩指引，并展现出医疗器械业务的强劲增长。
05-18 18:16
MDxHealth Reports Q1 2026 Results: Full Earnings Call Transcript
On Wednesday, MDxHealth (NASDAQ:MDXH) discussed first-quarter financial results...
05-14 05:08
